about
On the relationship between drug's size, cell membrane mechanical properties and high levels of multi drug resistance: a comparison to published data.Toward a mechanical control of drug delivery. On the relationship between Lipinski's 2nd rule and cytosolic pH changes in doxorubicin resistance levels in cancer cells: a comparison to published data.On some aspects of the thermodynamic of membrane recycling mediated by fluid phase endocytosis: evaluation of published data and perspectives.Nongenomic effects of cisplatin: acute inhibition of mechanosensitive transporters and channels without actin remodeling.Glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer questionImpact of maternal dietary fat supplementation during gestation upon skeletal muscle in neonatal pigsResistance to cancer chemotherapy: failure in drug response from ADME to P-gp.Proton pump inhibitors for the treatment of cancer in companion animals.Cariporide and other new and powerful NHE1 inhibitors as potentially selective anticancer drugs--an integral molecular/biochemical/metabolic/clinical approach after one hundred years of cancer research.Teaching new dogs old tricks: membrane biophysical properties in drug delivery and resistance.Acid-mediated Lipinski's second rule: application to drug design and targeting in cancerMicroenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.Cellular acidification as a new approach to cancer treatment and to the understanding and therapeutics of neurodegenerative diseases.Physical and biological characteristics of multi drug resistance (MDR): An integral approach considering pH and drug resistance in cancer.The bio-physics of condensation of divalent cations into the bacterial wall has implications for growth of Gram-positive bacteria.Inward relocation of exogenous phosphatidylserine triggered by IGF-1 in non-apoptotic C2C12 cells is concentration dependent.Cyclosporin-A inhibits stretch-induced changes in myosin heavy chain expression in C2C12 skeletal muscle cells.Static stretch promotes MEF2A nuclear translocation and expression of neonatal myosin heavy chain in C2C12 myocytes in a calcineurin- and p38-dependent manner.A quantitative systems pharmacology approach, incorporating a novel liver model, for predicting pharmacokinetic drug-drug interactions.Mechanism of mucosal permeability enhancement of CriticalSorb® (Solutol® HS15) investigated in vitro in cell cultures.Erratum: Glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer question.Proton dynamics in cancer.C2C12 skeletal muscle cells exposure to phosphatidylcholine triggers IGF-1 like-responses.Physics of nail conditions: why do ingrown nails always happen in the big toes?Can long range mechanical interaction between drugs and membrane proteins define the notion of molecular promiscuity? Application to P-glycoprotein-mediated multidrug resistance (MDR).The "multi" of drug resistance explained by oscillating drug transporters, drug-membrane physical interactions and spatial dimensionality.Stretch-induced activation of ERK in myocytes is p38 and calcineurin-dependentNon-genomic steroid effects: merging membrane fluidity and receptor-mediated responsesTheoretical evaluation of wall teichoic acids in the cavitation-mediated pores formation in Gram-positive bacteria subjected to an electric field
P50
Q33346419-621819F6-285E-4850-B4F7-97E5050F3EBAQ33419395-4CF31B02-CAB9-4B08-B8AF-7F8C183376C6Q33518671-90AE1D97-B3F5-4A04-8EF6-09ECE8061838Q34137980-B66E7785-5F5A-4510-A667-3E9C0ADF5898Q34459681-9109F819-979E-462B-8B88-D504B00A5DBCQ34570337-9062CB5D-150C-4035-9ECB-BA611D4F700CQ35852614-679192F5-166D-4880-A03F-1269D7648F56Q36027301-5D7E26E7-D66B-4756-AA42-E06076768A10Q37304956-09CB28B8-E13D-426F-99FB-1582F8397919Q37901082-8678E974-C98A-4348-A67F-EF3018499A16Q38200959-CE3E7F9E-0FC5-4959-8E55-9922F219ABAFQ38581012-6373A1FE-BACE-49DA-B599-37853ECB2DECQ38963473-7DD0ADE9-497C-4816-A250-8AA86D5644F9Q39080314-5CAB66C6-63B4-4514-8778-443672A4BE73Q39112156-9B0CB56E-4843-48E9-AA41-AE617B6D523DQ40368950-EB4CC1E1-72AC-41F7-BD48-EBC5E764669BQ40483677-9EE43460-93B3-40DB-BA41-A12895A39FADQ40504610-56CD386F-4B16-425D-9DEC-A74F3863ECFBQ41072555-EA0BF4E3-2510-44DE-9B59-DE6BD6A19058Q42133676-50113752-5590-4650-8EE4-F78B91DA634DQ42430916-D37C8993-32CB-4B38-8D98-595CB67231DAQ42730234-5C666538-70D2-48A4-ABA8-5C80CE187765Q46547439-54FE96AD-53D5-4795-B365-447521287DF7Q46824589-19DB42AE-3D86-4A40-9192-D92BAAF70033Q48014810-164C38DC-EA6A-495E-915A-414C9A6D997DQ51601160-15A91801-0AEF-40E1-9F15-E5664CF3AF6AQ79714268-51CE885D-FE66-4E90-B399-ED35B6BE13D4Q81249836-824480F5-030F-4D6E-8155-266E4FB11EE1Q86252693-3FE61589-716A-41BA-A3E0-BAD15DD49363
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Cyril Rauch
@ast
Cyril Rauch
@en
Cyril Rauch
@es
Cyril Rauch
@nl
Cyril Rauch
@sl
type
label
Cyril Rauch
@ast
Cyril Rauch
@en
Cyril Rauch
@es
Cyril Rauch
@nl
Cyril Rauch
@sl
prefLabel
Cyril Rauch
@ast
Cyril Rauch
@en
Cyril Rauch
@es
Cyril Rauch
@nl
Cyril Rauch
@sl
P106
P1153
15835823000
P21
P31
P496
0000-0001-8584-420X